Form 4: Travere Therapeutics Director, Gary A. Lyons, Reports Acquisition and Disposal of Common Stock

Gary A. Lyons, a director of Travere Therapeutics, reports acquiring and disposing of common stock and stock options on May 15, 2025, according to a Form 4 filing.

Summary

• On May 15, 2025, Gary A. Lyons, a director of Travere Therapeutics, filed a Form 4.
• The filing reports the acquisition of 6,500 shares of common stock at $0 per share and the disposal of 57,500 shares.
• Lyons also acquired 19,500 stock options with an exercise price of $21.15, exercisable from May 15, 2026, and expiring on May 15, 2035.
• These transactions were part of an automatic equity grant under the company's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
• The equity award vests over a one-year period.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of stock options and shares by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Negatives

• The disposal of 57,500 shares by a director could be interpreted negatively by some investors, although the overall context of the transactions suggests it's part of a planned compensation program.

Risks

• The vesting schedule of the stock options and equity awards could influence the director's decisions regarding their holdings in the company.
• Market conditions and the company's performance could impact the value of the stock options and shares acquired.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grant suggests an ongoing commitment to incentivizing non-employee directors.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's value and prospects.

Comparison to Industry Standards

• Equity compensation for non-employee directors is a common practice in the pharmaceutical industry.
• The vesting schedule of one year is fairly standard for such grants.
• The specific terms of the equity incentive plan would need to be compared to those of peer companies like BioMarin Pharmaceutical, Sarepta Therapeutics, and Vertex Pharmaceuticals to assess its competitiveness.

Stakeholder Impact

• The transactions may have a minor impact on shareholders' perception of the company, depending on how they interpret the director's stock activity.
• The equity grant serves as an incentive for the director to contribute to the company's success.

Key Dates

Keywords

Travere Therapeutics, Director, Gary A. Lyons, Form 4, Stock Options, Equity Incentive Plan, Common Stock, Acquisition, Disposal